Dr Aditya Shreenivas speaks to ecancer about penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.

This trial explores the effectiveness of penpulimab combined with chemotherapy for first-line recurrent metastatic nasopharyngeal carcinoma, achieving FDA approval.

It includes 291 patients, with 144 receiving penpulimab and 147 receiving a placebo.

The penpulimab group shows a median progression-free survival of 9.6 months, compared to 7 months for the placebo.

The study notes fewer immune-related adverse events and anticipates future overall survival data.